TechTalk Blog
Avocet 3D Images secures large Yacht Contract

Avocet 3D has just been awarded a large contract to visualize the interior and exterior of a yacht designed by Gregory C. Marshall N.A. Ltd. The project will consist of creating images of major interior spaces showing the stunning decor and design layout. Avocet 3D Images will also create images of the exterior in a variety of situations such as underway and a anchour.

Avocet 3D Images to work on Ocean Technology Park Project

Avocet 3D Images has just received the go ahead to proceed on visualization of the proposed UVic Ocean Technology Park to be based on the west shore of Saanich peninsula on Vancouver Island. Using new techniques, Avocet 3D can create a computer model that allows the designers and engineers to manipulate the virtual environment to discover any conflicts that may exist in the design. Once the initial model has been created and signed off, photorealistic images will be created of the site to be used in marketing and sales The centre will house a tank testing facility, for testing ocean going vessels in a variety of situations. It will also consist of other related companies that either research the ocean environment or capitalize on products that pertain to the ocean environment.

Work on visualization will commence immediately.


For more information:
Dennet Woodland
Avocet 3D Images
250.483.3264

Avocet 3D Images to work on Ocean Technology Park Project

Avocet 3D Images has just received the go ahead to proceed on visualization of the proposed UVic Ocean Technology Park to be based on the west shore of Saanich peninsula on Vancouver Island. Using new techniques, Avocet 3D can create a computer model that allows the designers and engineers to manipulate the virtual environment to discover any conflicts that may exist in the design. Once the initial model has been created and signed off, photorealistic images will be created of the site to be used in marketing and sales The centre will house a tank testing facility, for testing ocean going vessels in a variety of situations. It will also consist of other related companies that either research the ocean environment or capitalize on products that pertain to the ocean environment.

IDC names President & CEO

Brent Sternig has officially been named president and chief executive of the University of Victoria's Innovation Development Corporation. Sternig had been acting CEO for the past six months, replacing Doug Tolson, and had helped to develop a new strategic plan for the IDC, an organization that manages UVic's intellectual property portfolio.

Wellcome Trust Centre for Human Genetics Selects GenoLogics

GenoLogics today announced that Wellcome Trust is deploying its lab and data management solution for genomics, including integrations to next generation sequencing platforms.

 

The Wellcome Trust Centre for Human Genetics (WTCHG) undertakes research into the genetic basis of multi-factorial diseases such as hypertension, diabetes, heart disease, infectious diseases, psychiatric disorders and multiple sclerosis. The Genomics Group of the Centre not only conducts research and development, but also provides a number of services for the Centre and other University of Oxford groups. Areas of interest include microarray, high-throughput quantitative gene expression, high-throughput genotyping and other specialties.

 

According to Dr. Ioannis Ragoussis, Head of Genomics at the Wellcome Trust Centre for Human Genetics, “we selected Geneus for our centralized lab and data management platform because of its flexibility to automate data capture from a wide range of genomics instruments and applications, while allowing us to more efficiently track samples and QC results across numerous projects.” Dr. Ragoussis went on to say, “a primary consideration in our selection of Geneus was the platform’s capability to fully integrate to our next generation sequencing instruments from Illumina and Roche, and automatically pipeline data for downstream analysis.”

 

Since Geneus is designed for the unique needs of genomics research facilities, the lab and data management solution can be deployed quickly to provide the Centre with immediate value. Pre-configured integrations across many instruments, including Illumina’s Genome Analyzer, means Geneus will improve the efficiency of the Centre as well as the quality of the data. This includes configuring the system for range of applications such as ChIP sequencing, resequencing, whole genome sequencing and genome wide association studies. By using GenoLogics’ web collaboration tool, LabLink, and adaptive reporting engine, the Centre will also be able to easily generate and share results with its customers.

 

“Geneus is one of the only solutions available in the marketplace today that is purpose built for genomics labs and provides seamless integrations to many instruments including next generation sequencing platforms”, said Michael Ball, CEO for GenoLogics. “For high throughput research facilities such as Wellcome Trust, Geneus provides a centralized yet flexible solution that is capable of managing large volumes of data from sample submissions to results.”

 

GenoLogics provides research organizations with informatics solutions for multiple sciences and technologies. Delivered as a set of modules on a common informatics platform, our solutions manage lab operations, while integrating research data across domains and providing superior sample traceability. Along with an automated bioinformatics pipelining system and reporting engine, our solutions transform data into results and enable advanced analysis.

 

 


About GenoLogics

GenoLogics is the leading provider of informatics solutions for translational research, spanning both the discovery and biomedical research domains. Our science purposed modules for discovery research are complemented by a highly configurable, integrating lab informatics platform that is scalable to service many labs and sciences across an organization. Our Biomedical Informatics product suite allows labs to track and manage their biospecimen and clinical annotations data, while aggregating results with our Research Informatics solution for a holistic view. For more information, please visit www.genologics.com.

 

 

###

 

 

GenoLogics Contact:                                                 

Bobbi Leach

Manager, Marketing Communications

250.483.7063

roberta.leach@genologics.com

Sternig named IDC President & CEO

Brent Sternig has officially been named president and chief executive of the University of Victoria's Innovation Development Corporation. Sternig had been acting CEO for the past six months, replacing Doug Tolson, and had helped to develop a new strategic plan for the IDC, an organization that manages UVic's intellectual property portfolio.

VITP to Host Internationally Acclaimed Conference

[No text]

Joint BioEnergy Institute Selects GenoLogics

GenoLogics today announced that the Joint BioEnergy Institute (JBEI), a U.S. Department of Energy bioenergy research center based in Emeryville, California, is deploying its lab and integrated data management solution for multiple sciences.

 

JBEI is a scientific partnership that is led by Lawrence Berkeley National Laboratory and includes the Sandia National Laboratories, the University of California campuses of Berkeley and Davis, the Carnegie Institution for Science and the Lawrence Livermore National Laboratory. JBEI’s primary scientific mission is to advance the development of the next generation of biofuels – liquid fuels derived from the solar energy stored in plant biomass.

 

“The GenoLogics solution has the capabilities we require to integrate data from different sciences and technologies, while tracking samples across multiple experiments and projects all in a single lab and data management system,” said Dr. Paul Adams, JBEI’s Vice President of Technology. “The GenoLogics system will also allow us to easily generate reports showing data from multiple sciences and automate our data pipelining for integrated analysis.”

 

Since GenoLogics lab and data management solutions are built for the unique needs of research organizations, they are already designed to provide an integrated view of data from the type of sciences and technologies the JBEI employs. Pre-configured integrations across many instruments, combined with the GenoLogics reporting engine, means the solution will also improve the data quality and integrated analysis that is needed to advance the JBEI research.

 

“Our multi-science informatics platform is ideal for the alternative energy research the JBEI is conducting, as it seamlessly aggregates data from different applications and integrates the data in a contextually relevant way”, said Michael Ball, CEO for GenoLogics. “As the life sciences market matures, it is becoming more common for our clients to require a common data management system that can be deployed across different sciences, technologies and facilities.”

 

GenoLogics provides research organizations with informatics solutions for multiple sciences and technologies. Delivered as a set of modules on a common informatics platform, our solutions manage lab operations, while integrating research data across domains and providing superior sample traceability. Along with an automated bioinformatics pipelining system and reporting engine, our solutions transform data into results and enable advanced analysis.

 


About GenoLogics

GenoLogics is the leading provider of informatics solutions for translational research, spanning both the discovery and biomedical research domains. Our science purposed modules for discovery research are complemented by a highly configurable, integrating lab informatics platform that is scalable to service many labs and sciences across an organization. Our Biomedical Informatics product suite allows labs to track and manage their biospecimen and clinical annotations data, while aggregating results with our Research Informatics solution for a holistic view. For more information, please visit www.genologics.com.

 

 

###

 

 

GenoLogics Contact:                                                 

Bobbi Leach

Manager, Marketing Communications

250.483.7063

roberta.leach@genologics.com

Protox announces initiation of placebo controlled Phase 2 BPH study

VANCOUVER, Jan. 12 – Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced the initiation of a double-blinded placebo controlled Phase 2 study of PRX302 (study name: TRIUMPH) in patients with benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide. The trial will evaluate the efficacy of PRX302 versus placebo using the optimal treatment volume established in the open-label Phase 2 study results announced in November, 2008.

"Results from our open-label Phase 2 study demonstrated that PRX302 has the potential to establish a new standard of care for the treatment of BPH," said Dr. Fahar Merchant, President and Chief Executive Officer of Protox. "With results from TRIUMPH expected in the second half of 2009, we are confident this study will validate the value of PRX302 to our potential partners, and most importantly, patients suffering from BPH."

The trial's primary endpoint will be to determine efficacy of PRX302 as demonstrated by a statistically significant change in International Prostate Symptom Score (IPSS) from baseline when compared to placebo. Secondary endpoints will be the measurement in change from baseline of the Quality of Life (QoL) score, Peak Urinary Flow Rate (Qmax) and Post-Voiding Residual urine volume (PVR) when compared to placebo. The trial will also continue to assess safety and tolerability of PRX302. Results from the three month follow-up period of the Phase 2 study released in November, 2008 were very positive, with PRX302 demonstrating significant symptomatic relief while maintaining an excellent safety profile in men with moderate to severe BPH. In addition, 12 month follow-up results from the Phase 1 BPH study, completed in October 2008, indicated that PRX302 continues to show durable therapeutic benefit for at least one year following a single treatment.

   

About TRIUMPH

In this double-blinded placebo controlled Phase 2 study, up to 72 patients with moderate to severe BPH will be randomized 2:1 (treatment:placebo). Each patient will either receive PRX302 (3(micro)g/ml) or placebo at a volume equivalent to 20 percent of the total prostate volume with a minimum 1.5 mL per deposit. Dosing for each arm will be delivered via a single ultrasound-guided injection into each lobe of the prostate. Eligible patients will not have received alpha-blockers for at least 4 weeks prior to treatment and will not have been treated with 5 alpha-reductase inhibitors. Efficacy will be assessed based on symptomatic relief, prostate shrinkage and urinary flow measurements.

   

About BPH

BPH is a common urological condition characterized by painful and bothersome symptoms that include difficulty in initiating a urine stream, a sense of urgency, dribbling, incomplete emptying of the bladder, waking several times during the night to urinate and sometimes the presence of blood in the urine. More than half of all men will have symptoms of BPH by the age of 60 and as many as 90% may suffer from BPH after the age of 80. Current oral therapies mainly provide symptomatic relief, may take months before they take effect and can trigger a range of side effects including sexual dysfunction and hypotension. It is estimated that in the seven largest global markets approximately 10 million men are treated annually with oral therapies and these products encompass approximately U.S. $3 billion of sales each year. Surgical options, including minimally invasive procedures, can cause sexual dysfunction, incontinence as well as other more serious procedure-related effects. Surgical measures can require significant recovery time and may require catheterization for up to several weeks post-treatment. Nearly 600,000 surgical procedures are conducted annually in the seven largest markets.

   

About PRX302

PRX302 is the lead drug in the company's PORxin(TM) technology platform. PORxin drugs are pore-forming pro-drugs that are activated by specific proteases produced at elevated levels on the surface of target cells. PRX302 has been generated by engineering the naturally occurring toxin proaerolysin so that it is activated by prostate-specific antigen (PSA), an enzyme that is overproduced in patients suffering from prostate cancer and BPH (benign prostatic hyperplasia or enlarged prostate). Once activated, the drug punches holes in the cells causing the contents to leak out and ultimately cell death.

   

About Protox

Protox Therapeutics is a leader in advancing novel, receptor targeted fusion proteins. Two novel drug candidates derived from the company's INxin(TM) and PORxin(TM) platforms are being developed in three clinical programs. A Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA and EMEA. A phase 2a clinical trial evaluating PRX302 (PORxin) for the treatment of localized prostate cancer is ongoing and positive final Phase 2 results from Protox's lead program using PRX302 to treat benign prostatic hyperplasia (enlarged prostate) were recently released. Protox is also collaborating with the U.S. National Institutes of Health (NIH) on a research program focused on the discovery of next generation fully human targeted therapeutics.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox' current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Avocet 3D Images to work on Ocean Technology Park Project

Avocet 3D Images has just received the go ahead to proceed on visualization of the proposed UVic Ocean Technology Park to be based on the west shore of Saanich peninsula on Vancouver Island. Using new techniques, Avocet 3D can create a computer model that allows the designers and engineers to manipulate the virtual environment to discover any conflicts that may exist in the design. Once the initial model has been created and signed off, photorealistic images will be created of the site to be used in marketing and sales The centre will house a tank testing facility, for testing ocean going vessels in a variety of situations. It will also consist of other related companies that either research the ocean environment or capitalize on products that pertain to the ocean environment.